IRIS
MONTIRONI, Rodolfo
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 30.100
EU - Europa 13.826
AS - Asia 3.635
Continente sconosciuto - Info sul continente non disponibili 52
SA - Sud America 20
AF - Africa 10
OC - Oceania 7
Totale 47.650
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 30.065
UA - Ucraina 3.817
IE - Irlanda 2.233
TR - Turchia 1.883
SE - Svezia 1.770
DE - Germania 1.740
DK - Danimarca 1.430
IT - Italia 1.318
FI - Finlandia 767
KR - Corea 749
SG - Singapore 723
GB - Regno Unito 575
IN - India 131
CN - Cina 94
FR - Francia 53
EU - Europa 52
BE - Belgio 51
CA - Canada 32
RU - Federazione Russa 17
BR - Brasile 15
VN - Vietnam 14
JP - Giappone 13
ID - Indonesia 11
NL - Olanda 11
CH - Svizzera 7
RO - Romania 6
AU - Australia 5
BG - Bulgaria 4
IL - Israele 4
RS - Serbia 4
AE - Emirati Arabi Uniti 3
CI - Costa d'Avorio 3
CO - Colombia 3
EG - Egitto 3
LU - Lussemburgo 3
MX - Messico 3
PL - Polonia 3
AT - Austria 2
CZ - Repubblica Ceca 2
ES - Italia 2
GR - Grecia 2
HK - Hong Kong 2
IR - Iran 2
KE - Kenya 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
SA - Arabia Saudita 2
UY - Uruguay 2
BY - Bielorussia 1
EE - Estonia 1
HR - Croazia 1
HU - Ungheria 1
IS - Islanda 1
JO - Giordania 1
KZ - Kazakistan 1
LI - Liechtenstein 1
MY - Malesia 1
NG - Nigeria 1
NP - Nepal 1
SK - Slovacchia (Repubblica Slovacca) 1
TN - Tunisia 1
Totale 47.650
Salva come PNG Salva come JPEG
Città #
Jacksonville 3.923
Chandler 3.305
Fairfield 3.242
Dublin 2.229
Ashburn 1.912
Des Moines 1.838
Wilmington 1.762
Woodbridge 1.433
Houston 1.238
Seattle 1.195
Boardman 1.132
Cambridge 1.008
Lawrence 908
Princeton 908
San Mateo 892
New York 792
Ann Arbor 600
San Diego 419
Centro 414
Milan 232
London 149
Pune 125
Norwalk 93
Washington 92
Redmond 79
Los Angeles 76
Beijing 67
Izmir 67
Falls Church 61
Helsinki 53
Brussels 49
Marche 48
Kilburn 44
Turin 43
Ancona 29
Rome 28
Porto 26
Prescot 26
Venice 26
New Bedfont 20
Tappahannock 20
Chiswick 17
Berlin 16
Auburn Hills 15
Hounslow 15
Acton 13
Dong Ket 13
Chicago 12
Ottawa 11
Wandsworth 11
Hanover 10
Southwark 10
Edinburgh 9
Forlì 9
Frankfurt am Main 9
Pesaro 9
Phoenix 9
Sheffield 9
Simi Valley 9
Strasbourg 9
Essen 8
Redwood City 8
Bologna 7
Montréal 7
Nanjing 7
Palermo 7
Torre Del Greco 7
Islington 6
Menlo Park 6
Saint Petersburg 6
Stockholm 6
São Paulo 6
Amsterdam 5
Fayetteville 5
Mountain View 5
Ostra Vetere 5
Torino 5
Toronto 5
Zurich 5
Appignano 4
Canosa di Puglia 4
Civitanova Marche 4
Jesi 4
Macerata 4
Marano di Valpolicella 4
Shanghai 4
Abidjan 3
Bari 3
Belgrade 3
Buffalo 3
Caserta 3
Castelfidardo 3
Castelnuovo Rangone 3
Dallas 3
Dubai 3
Frederico Westphalen 3
Fuzhou 3
Kagoya 3
Las Vegas 3
Montreal 3
Totale 31.004
Salva come PNG Salva come JPEG
Nome #
Designing novel immunocombinations in metastatic renal cell carcinoma 146
Germline and somatic mutations in prostate cancer: Focus on defective DNA repair, PARP inhibitors and immunotherapy 122
Role of DNA analysis and mutation of P53 gene in small dimension renal carcinomas. Biological significance and long-term follow-up 119
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients 112
Immunotherapy in genitourinary cancers: Where are we going? 112
Green fluorescent protein as indicator of non-viral transient transfection efficiency in endometrial and testicular biopsies 105
Atypical foci, suspicious but not diagnostic of malignancy in prostate needle biopsies (also referred to as "atypical small acinar proliferation suspicious for but not diagnostic of malignancy") 105
Chromosomal Abnormalities in Macroscopically Normal Urothelium in Patiens with Bladder pT1 and pT2a Urothelial Carcinoma: a Fluorescence in situ hybridisation Study and Correlation with Histologic Features. 101
Computer assisted discrimination of glioblastomas 101
Clinical performance and utility of a NNMT-based urine test for bladder cancer 99
Microbiome and cancers, with focus on genitourinary tumors 99
Metabolic phenotype of bladder cancer 99
Tumor VEGF expression correlates with tumor stage and identifies prognostically different groups in clear cell renal cell carcinoma patients 98
Activity and expression of nitric oxide synthase in rat bladder after sacral neuromodulation 97
Prognostic value of CD44 expression in penile squamous cell carcinoma: a pilot study. 96
Sequential or Concomitant Inhibition of Cyclin-Dependent Kinase 4/6 Before mTOR Pathway in Hormone-Positive HER2 Negative Breast Cancer: Biological Insights and Clinical Implications 95
Expression of pi-class glutathione S-transferase: two populations of high grade prostatic intraepithelial neoplasia with different relations to carcinoma 93
Bone metastases in patients with metastatic renal cell carcinoma: Are they always associated with poor prognosis? 93
Ciliary neurotrophic factor (CNTF) and its receptor (CNTFRα) signal through MAPK/ERK pathway in human prostate tissues: a morphological and biomolecular study 93
Molecular diagnostics in uro-oncology 92
HER2 expression and gene amplification in pT2a Gleason score 6 prostate cancer incidentally detected in cystoprostatectomies: comparison with clinically detected andreogen-dependent and androgen-independent cancer. 91
From undergraduate medical school student to visible pathologist 89
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 89
Urothelial carcinoma of the bladder, lipid cell variant: clinicopathologic findings and LOH analysis 88
Immunohistochemical expression of somatostatin receptor subtypes in prostate tissue from cystoprostatectomies with incidental prostate cancer. 88
Secondary neoplasms of the urinary system and male genital organs. 88
Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in Renal Cell Carcinoma 88
Seminal Vesicle Intraepithelial Neoplasia Versus Basal Cell Hyperplasia in a Seminal Vesicle. 87
Cardiac myxoma with glandular elements metastatic to the brain 12 years after the removal of the original tumor 87
Cytometric Evidence That Cervical Intraepithelial Neoplasia-i and Neoplasia-ii Are Dysplasias Rather Than True Neoplasias - An Image-analysis Study of Factors Involved In the Progression of Cervical Lesions 87
Metabolic Alterations in Renal and Prostate Cancer 86
Interactive digital slides with heat maps: a novel method to improve the reproducibility of Gleason grading 85
International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 1: specimen handling 85
Quantitative-analysis of Prostatic Intraepithelial Neoplasia On Tissue-sections. 85
Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and proliferation index (ki67-MIB1) 84
alpha-methylacyl-CoA racemase (P504S)/34 beta E12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy 84
BAP1, PBRM1 and SETD2 in clear-cell renal cell carcinoma: Molecular diagnostics and possible targets for personalized therapies 84
Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications 84
TGFb1 immunohistochemistry in goiter; comparison of patients with recurrence or non recurrence 83
Morphological diagnosis of urothelial neoplasms. 83
Computer assisted analysis of medulloblastoma: a cytological study 83
The Role of Focal Therapy in the Management of Localised Prostate Cancer: A Systematic Review. 81
Handling and pathology reporting of specimens with carcinoma of the urinary bladder, ureter, and renal pelvis 81
Classification and grading of the non-invasive urothelial neoplasms: recent advances and controversies. 81
Succinate dehydrogenase-deficient renal cell carcinoma: Detailed characterization of 11 tumors defining a unique subtype of renal cell carcinoma 81
Grading of Chromophobe Renal Cell Carcinoma: Do We Need It? 81
Is There a Role for Immunotherapy in Prostate Cancer? 81
Editorial comment on: validation of the contemporary epstein criteria for insignificant prostate cancer in European men. 80
PD-1 blockade therapy in renal cell carcinoma: current studies and future promises 80
Variation in reporting of cancer extent and benign histology in prostate biopsies among European pathologists. 79
Expert system support using a Bayesian belief network for the classification of endometrial hyperplasia 79
Urothelial papillary lesions. Development of a Bayesian Belief Network for diagnosis and grading 79
"Pathological" reflection on European urology: extended, saturation, and systematic prostate biopsies. 79
Joint appraisal of the radical prostatectomy specimen by the urologist and the uropathologist: together, we can do it better 79
Statistical histometry of the basal cell secretory cell bilayer in prostatic intraepithelial neoplasia. 79
Impact of prostate cancer multifocality on its biology and treatment. 79
VEGF and VEGFR polymorphisms affect clinical outcome in advanced renal cell carcinoma patients receiving first-line sunitinib 79
2004 WHO classification of the renal tumors of the adults. 79
A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. 79
Cognitive zonal fusion biopsy of the prostate: Original technique between target and saturation. 79
Pd-l1 inhibitors for the treatment of prostate cancer 79
Urothelial and incidental prostate carcinoma in prostates from cystoprostatectomies for bladder cancer: is there a relationship between urothelial and prostate cancer? 78
Improving inter-observer agreement and certainty level in diagnosing and grading papillary urothelial neoplasms: usefulness of a Bayesian belief network. 78
Do DNA methylation and histone acetylation play a role in clear cell renal carcinoma? Analysis of radical nephrectomy specimens in a long-term follow-up. 78
Perivascular epithelioid cell tumor (PEC-ome) of the prostate: ultrasound feature in case report 78
Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors 78
Extent of cancer of less than 50% in any prostate needle biopsy core: how many millimeters are there? 78
Pathology in prostate research: Optimizing tissue quality 77
HtrA1 in human urothelial bladder cancer: a secreted protein and a potential novel biomarker. 77
Clinicopathologic analysis of upper urinary tract carcinoma with variant histology 77
[Gleason's grading of prostatic cancer: a current perspective]. 76
Chromatin texture signatures in nuclei from prostate lesions 76
Oligometastases in Genitourinary Tumors: Recent Insights and Future Molecular Diagnostic Approach 76
Diagnostic Criteria for Ductal Adenocarcinoma of the Prostate.Interobserver Variability among 20 Expert Uropathologists. 76
Changes produced in the urothelium by traditional and newer therapeutic procedures for bladder cancer. 75
Activity of chemokines in prostate and renal tumors and their potential role as future therapeutic targets 75
Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor 75
The 1996 European Urology Focus on Preneoplastic Lesions of the Prostate 75
Clinical Actionability of the Genomic Landscape of Metastatic Castration Resistant Prostate Cancer 75
Extramammary Paget disease of the penis closely mimicking the penile analogue of stratified mucin-producing intraepithelial lesion 75
Screening for prostatic cancer and its evolution within Britain 74
Aneuploidy and nuclear features of prostatic intraepithelial neoplasia (PIN). 74
D2-40 immunoreactivity in penile squamous cell carcinoma: a marker of aggressiveness 74
Genitourinary cancers: molecular determinants for personalized therapies 74
The human microbiota and prostate cancer: Friend or foe? 74
Emerging prognostic biomarkers in testicular germ cell tumors: Looking beyond established practice 74
Villous adenoma of the urinary tract: a report of 23 cases, including 8 with coexistent adenocarcinoma 73
Basal cell hyperplasia and basal cell carcinoma of the prostate: a comprehensive review and discussion of a case with c-erbB-2 expression. 73
Effect of complete androgen blockade on pathologic stage and resection margin status of prostate cancer: Progress pathology report of the Italian PROSIT study 73
2004 World Health Organization Classification of the Noninvasive Urothelial Neoplasms: Inherent Problems and Clinical Reflections 73
Pseudocarcinomatous hyperplasia associated with primary lymphoma in the urinary bladder: a case report 73
Carcinoma of the prostate: inherited susceptibility, somatic gene defects and androgen receptors 72
Pathology of prostate cancer and focal therapy ('male lumpectomy'). 72
Critical evaluation of the prostate from cystoprostatectomies for bladder cancer: insights from a complete sampling with the whole mount technique 72
Evaluation of prognostic factors in radical prostatectomy specimens with cancer 72
Adult primary paratesticular mesenchymal tumors with emphasis on a case presentation and discussion of spermatic cord leiomyosarcoma. 72
A randomized phase IIb presurgical study of finasteride vs. low-dose flutamide vs. placebo in men with prostate cancer. Efficacy monitored by karyometry 72
The route to personalized medicine in bladder cancer: where do we stand? 72
Neoadjuvant hormone treatment with leuprolide acetate depot 3.75 mg and cyproterone acetate, before radical prostatectomy: a randomized study 71
Upregulation of Tissue and Urinary Nicotinamide N-Methyltransferase in Bladder Cancer: Potential for the Development of a Urine-Based Diagnostic Test. 71
Totale 8.387
Salva come PNG Salva come JPEG
Categoria #
all - tutte 249.607
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 249.607
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019102 0 0 0 0 0 0 0 0 0 0 5 97
2019/20204.418 20 3 790 14 778 21 786 8 780 32 78 1.108
2020/202112.955 612 1.238 1.572 269 1.517 1.477 1.215 933 1.163 1.130 1.275 554
2021/20226.642 620 1.542 134 320 93 552 203 432 475 538 386 1.347
2022/202311.128 1.119 780 604 975 804 2.588 11 659 2.830 51 421 286
2023/20245.307 1.239 165 345 998 1.049 1.158 112 111 20 110 0 0
Totale 48.344